DuPont de Nemours, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DuPont de Nemours, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $5.25B | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $5.20B | Feb 12, 2021 |
| FY2019 | Sep 30, 2019 | $5.43B | Feb 14, 2020 |
| FY2019 | Jun 30, 2019 | $5.47B | Feb 14, 2020 |
| FY2019 | Mar 31, 2019 | $5.41B | Feb 14, 2020 |
| FY2019 | Dec 31, 2018 | $5.46B | Feb 14, 2020 |
| FY2019 | Sep 30, 2018 | $5.68B | Feb 14, 2020 |
| FY2019 | Jun 30, 2018 | $5.86B | Feb 14, 2020 |
| FY2019 | Mar 31, 2018 | $5.60B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $20.07B | Feb 11, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.69B | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | $1.80B | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | $1.75B | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | $1.61B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.69B | Feb 17, 2026 |
| FY2025 | Sep 30, 2024 | $1.71B | Feb 17, 2026 |
| FY2025 | Jun 30, 2024 | $1.72B | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $1.60B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $6.61B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $13.02B | Feb 14, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $20.07B | Feb 15, 2018 |
| FY2017 | Sep 30, 2017 | $15.35B | Feb 15, 2018 |
| FY2017 | Jun 30, 2017 | $13.83B | Feb 15, 2018 |
| FY2017 | Mar 31, 2017 | $13.23B | Feb 15, 2018 |
| FY2017 | Dec 31, 2016 | $13.02B | Feb 15, 2018 |
| FY2017 | Sep 30, 2016 | $12.48B | Feb 15, 2018 |
| FY2017 | Jun 30, 2016 | $11.95B | Feb 15, 2018 |
| FY2017 | Mar 31, 2016 | $10.70B | Feb 15, 2018 |
| FY2017 | Dec 31, 2015 | $48.78B | Feb 15, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $4.53B | Feb 11, 2019 |
| FY2018 | Sep 30, 2018 | $4.65B | Feb 11, 2019 |
| FY2018 | Jun 30, 2018 | $6.27B | Feb 11, 2019 |
| FY2018 | Mar 31, 2018 | $5.20B | Feb 11, 2019 |
| FY2018 | Dec 31, 2017 | $3.42B | Feb 11, 2019 |
| FY2018 | Sep 30, 2017 | $3.17B | Feb 11, 2019 |
| FY2018 | Jun 30, 2017 | $3.07B | Feb 11, 2019 |
| FY2018 | Mar 31, 2017 | $3.04B | Feb 11, 2019 |
| FY2017 | Dec 31, 2016 | $2.45B | Feb 15, 2018 |
| FY2017 | Sep 30, 2016 | $2.64B | Feb 15, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($126.00M) | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | ($123.00M) | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | $59.00M | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | ($589.00M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($117.00M) | Feb 17, 2026 |
| FY2025 | Sep 30, 2024 | $454.00M | Feb 17, 2026 |
| FY2025 | Jun 30, 2024 | $178.00M | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $188.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $423.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $5.87B | Feb 14, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $193.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $203.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $192.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $536.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $557.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $565.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $689.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $1.07B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $657.00M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $1.59B | Feb 11, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $976.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $891.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.47B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.60B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.49B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $2.06B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $3.03B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.62B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $2.95B | Feb 11, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $588.00M | Feb 15, 2023 |
| FY2022 | Dec 31, 2021 | $2.28B | Feb 15, 2023 |
| FY2022 | Dec 31, 2020 | $4.10B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.41B | Feb 11, 2022 |
| FY2018 | Dec 31, 2018 | $4.73B | Feb 11, 2019 |
| FY2018 | Dec 31, 2017 | ($765.00M) | Feb 11, 2019 |
| FY2018 | Dec 31, 2016 | ($2.96B) | Feb 11, 2019 |
| FY2017 | Dec 31, 2015 | $7.61B | Feb 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.58B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $36.64B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $38.55B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $41.36B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $45.71B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $70.90B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $69.35B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $187.86B | Feb 12, 2021 |
| FY2018 | Jan 1, 2018 | $192.42B | Feb 11, 2019 |
| FY2019 | Dec 31, 2017 | $191.91B | Feb 14, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.47B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $12.84B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $13.83B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $14.34B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $18.66B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $31.83B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $27.79B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $91.96B | Feb 14, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.92B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $23.35B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $24.28B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $26.57B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $26.43B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $38.50B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $40.99B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $94.29B | Feb 14, 2020 |
| FY2018 | Jan 1, 2018 | $100.29B | Feb 11, 2019 |
| FY2018 | Dec 31, 2017 | $100.33B | Feb 11, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.92B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $7.56B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $7.66B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $16.66B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $16.98B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $16.04B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $22.14B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $34.50B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $34.82B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $15.27B | Feb 11, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.28B) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($23.08B) | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | ($22.87B) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | ($21.07B) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($23.19B) | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | ($11.59B) | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | ($8.40B) | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $30.26B | Feb 14, 2020 |
| FY2018 | Jan 1, 2018 | $29.15B | Feb 11, 2019 |
| FY2018 | Dec 31, 2017 | $29.21B | Feb 11, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $715.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.79B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $2.39B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $3.66B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.97B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $2.54B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $1.54B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $8.55B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $13.44B | Feb 11, 2019 |
| FY2018 | Dec 31, 2016 | $6.61B | Feb 11, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $7.86B | Feb 15, 2024 |
| FY2023 | Dec 31, 2022 | $8.15B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $10.63B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $15.61B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | ($15.62B) | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | ($12.64B) | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $32.12B | Feb 11, 2019 |
| FY2017 | Dec 31, 2016 | $21.09B | Feb 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | (1) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 17, 2026 |
| FY2025 | Sep 30, 2024 | 1 | Feb 17, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 11 | Feb 14, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | (1) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 17, 2026 |
| FY2025 | Sep 30, 2024 | 1 | Feb 17, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 11 | Feb 14, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | 734.20M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | 738.57M | Feb 12, 2021 |
| FY2020 | Dec 31, 2018 | 784.14M | Feb 12, 2021 |
| FY2020 | Dec 31, 2017 | 780.49M | Feb 12, 2021 |
| FY2019 | Sep 1, 2017 | 779.51M | Feb 14, 2020 |
| FY2019 | Jan 1, 2017 | 414.27M | Feb 14, 2020 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $597.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $635.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $651.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $652.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $630.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $882.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.61B | Feb 11, 2022 |